Cyclacel Pharmaceuticals, Inc. (CYCC)
- Previous Close
2.2000 - Open
2.1000 - Bid 1.9600 x 100
- Ask 2.1300 x 100
- Day's Range
1.9501 - 2.2584 - 52 Week Range
1.9500 - 49.2800 - Volume
144,393 - Avg. Volume
171,909 - Market Cap (intraday)
25.917M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-33.4400 - Earnings Date Aug 12, 2025 - Aug 18, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops cancer medicines based on cell cycle, epigenetics, and mitosis biology in the United States and the United Kingdom. Its lead product, Plogosertib or plogo, is a PLK1 inhibitor, in solid tumors and hematological malignancies, which is in Phase 1/2 clinical trial. The company was founded in 1996 and is headquartered in Kuala Lumpur, Malaysia.
www.cyclacel.comRecent News: CYCC
View MorePerformance Overview: CYCC
Trailing total returns as of 5/16/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CYCC
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CYCC
View MoreValuation Measures
Market Cap
25.92M
Enterprise Value
22.78M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
15.57
Price/Book (mrq)
--
Enterprise Value/Revenue
529.77
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-160.18%
Return on Equity (ttm)
-1,950.23%
Revenue (ttm)
14k
Net Income Avi to Common (ttm)
-8.35M
Diluted EPS (ttm)
-33.4400
Balance Sheet and Cash Flow
Total Cash (mrq)
3.45M
Total Debt/Equity (mrq)
0.29%
Levered Free Cash Flow (ttm)
-13.25M